The date for the generics and biosimilars specialist Sandoz to spin out from its parent company Novartis (NOVN: VX) has been announced. 25 September 2023
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.